NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.
Olivier Litzka has been a partner with Paris-based Edmond de Rothschild Investment Partners (EdRIP) since 2006.
He invests primarily in European biotechnology and medtech companies as well as some investments in the United States. In addition to Endosense, he serves on the boards of Noxxon Pharma, ProBioDrug, SuperSonic Imagine, Sapiens Steering Brain Stimulation and JenaValve Technologies.
Up until its acquisition by AstraZeneca, he was also a member of the board of Novexel (France). Before joining EdRIP, Litzka spent six years with 3i’s life science venture capital practice, based first in Munich and then in Paris.
In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting for several years, both in Munich and Paris.
Litzka holds a Ph.D.
Dr. Peter Johann is a Managing General Partner of NGN Capital. Prior to NGN he had several positions in the healthcare industry.
He was the Division Head of Corporate Development at Boehringer Ingelheim where he was responsible for strategic planning, strategic projects, M&A, business development and licensing.
Prior to this Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader Oncology Products, at Boehringer Mannheim as Head of Business Development and Marketing Molecular Medicine and had Marketing, Sales and Business Development responsibilities at Boehringer Mannheim Biochemicals, among others, for collaborations in the field of Biopharmaceuticals.
Dr. Johann obtained his Ph.D. from the Technical University Munich. He currently serves on the Board of Directors of, Resverlogix Corp., Noxxon Pharma AG, Vivaldi Biosciences Inc. Endosense SA and Exosome Diagnostics Inc.
He previously served on the Board of Directors of Micromet, Inc. Horizon Pharma Inc.
Dr. Peperstraete has been involved in founding, operating and investing in the life science field for over 15 years. He is a Partner at NGN Capital, a $430MM cross-Atlantic venture capital firm in New York.
Previously, he was a medical entrepreneur (CRO), hospital manager, sales, product and marketing executive at Bristol Myers & Squibb (Singapore) and Novartis (Basel), and physician.
In recent years, Bernard has been closely involved with Potentia Pharma (Alcon) Artisan Pharma (AKP), Exosome Diagnostics, Noxxon, Daedalus Software, Maxcyte and several others.
Bernard earned his MBA at Harvard, his MD at the Katholieke Universiteit Leuven and his specialist diploma in Tropical Medicine, both in Belgium. He is a Kauffman Fellow and was a Belgian American Education Foundation fellow at Harvard.
He serves on the boards of ACT Biotech, Exosome Diagnostics. He previously served as a Director of Potentia Pharmaceuticals.
Dr. Axel Polack, has served as a member of our board of directors since May 2007.
Dr. Polack joined TVM Capital in 2000 and is a general partner for life sciences in the firm’s Munich office.
He currently serves on the board of Noxxon Pharma AG, Invendo Medical, f-star and Probiodrug AG. Dr. Polack’s main scientific fields of expertise are molecular and viral oncology, oncogene activation, gene regulation and molecular immunology.
He works intensively on the assessment of new investment opportunities in those areas, while also providing support to existing portfolio companies.
Before joining TVM Capital, Dr. Polack was general manager of Innovative Technologies Neuherberg GmbH (now Ascenion). Ascenion acts as a marketing partner to research institutions of the Helmholtz-Gemeinschaft, such as GSFNational Research Center for Environment and Health GmbH, which licenses patents and fosters start-up companies.
In the eight years prior to joining Ascenion, Dr.
Max Link, Ph.D. has been the Chairman of our board of directors since December 2002 and a director of Alexion since April 1992. From March 2001 to September 2003, Dr. Link was Chairman of the Board and CEO of Centerpulse AG, a medical implant company. From May 1993 to June 1994, Dr. Link was Chief Executive Officer of Corange (Bermuda), the parent company of Boehringer Mannheim Therapeutics, Boehringer Mannheim Diagnostics and DePuy Orthopedics. From 1992 to 1993, Dr. Link was Chairman of the Board of Sandoz Pharma, Ltd., a manufacturer of pharmaceutical products. From 1987 to 1992, Dr. Link was the Chief Executive Officer of Sandoz Pharma and a member of the Executive Board of Sandoz, Ltd., Basel. Prior to 1987, Dr. Link served in various capacities with the United States operations of Sandoz, including as President and Chief Executive Officer. Dr. Link is a director of Discovery Labs, Inc. and Human Genome Sciences, Inc.
CSO at Noxxon Pharma